Clarinex, Azomyr(desloratadine)
Aerinaze, Aerius, Azomyr, Clarinex, Neoclarityn (desloratadine) is a small molecule pharmaceutical. Desloratadine was first approved as Azomyr on 2001-01-15. It is used to treat allergic rhinitis perennial, allergic rhinitis seasonal, and urticaria in the USA. It has been approved in Europe to treat allergic rhinitis perennial, allergic rhinitis seasonal, and urticaria. The pharmaceutical is active against histamine H1 receptor.
Download report
Favorite
Searched
Commercial
Trade Name
FDA
EMA
Clarinex (generic drugs available since 2010-02-19)
CombinationsClarinex (generic drugs available since 2010-02-19, discontinued: Clarinex d)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| clarinex-d 12 hour | New Drug Application | 2022-11-14 |
| desloratadine | ANDA | 2023-02-06 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| allergic rhinitis perennial | EFO_1001417 | D012221 | J30.89 |
| allergic rhinitis seasonal | EFO_0003956 | D006255 | J30 |
| urticaria | EFO_0005531 | D014581 | L50 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
68 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Allergic rhinitis seasonal | D006255 | EFO_0003956 | J30 | — | 1 | 5 | 10 | 1 | 17 |
| Urticaria | D014581 | EFO_0005531 | L50 | — | — | 2 | 7 | 3 | 12 |
| Allergic rhinitis | D065631 | J30.9 | — | — | 7 | 1 | — | 8 | |
| Allergic rhinitis perennial | D012221 | EFO_1001417 | J30.89 | — | — | 2 | 3 | 1 | 6 |
| Chronic urticaria | D000080223 | L50.8 | — | — | 2 | 4 | — | 6 | |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | 1 | 1 | 3 | — | 4 |
| Asthma | D001249 | EFO_0000270 | J45 | — | — | 1 | 1 | 2 | 4 |
| Allergic conjunctivitis | D003233 | EFO_0007141 | H10.44 | — | — | 1 | 1 | — | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cold temperature | D003080 | — | — | 1 | — | — | 1 | ||
| Eczema | D004485 | HP_0000964 | L30.9 | — | — | 1 | — | — | 1 |
| Dermatitis | D003872 | HP_0011123 | L30.9 | — | — | 1 | — | — | 1 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | — | 1 | — | — | 1 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | 1 | — | — | 1 | |
| Chronic progressive multiple sclerosis | D020528 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | 1 | — | — | — | 1 | ||
| Rhinorrhea | D000086722 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 4 | — | — | — | — | 4 | ||
| Fasting | D005215 | EFO_0002756 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rhinitis | D012220 | EFO_0008521 | J31 | — | — | — | — | 4 | 4 |
| Pruritus | D011537 | HP_0000989 | L29 | — | — | — | — | 2 | 2 |
| Inflammation | D007249 | — | — | — | — | 1 | 1 | ||
| Heat stress disorders | D018882 | T67.2 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DESLORATADINE |
| INN | desloratadine |
| Description | Desloratadine is loratadine in which the ethoxycarbonyl group attached to the piperidine ring is replaced by hydrogen. The major metabolite of loratidine, desloratadine is an antihistamine which is used for the symptomatic relief of allergic conditions including rhinitis and chronic urticaria. It does not readily enter the central nervous system, so does not cause drowsiness. It has a role as a H1-receptor antagonist, an anti-allergic agent, a cholinergic antagonist and a drug metabolite. |
| Classification | Small molecule |
| Drug class | tricyclic histaminic-H1 receptor antagonists, loratadine derivatives (formerly-tadine) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1 |
Identifiers
| PDB | — |
| CAS-ID | 100643-71-8 |
| RxCUI | 275635 |
| ChEMBL ID | CHEMBL1172 |
| ChEBI ID | 291342 |
| PubChem CID | 124087 |
| DrugBank | DB00967 |
| UNII ID | FVF865388R (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
Clarinex - Organon
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,916 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
143,855 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more